

Manufacturer	NDC 11	Drug Name	Commercial Launch Date
GC Biopharma USA, Inc.	61476010405	Alyglo 10% Liquid 5g/50 ml	3/22/2024
GC Biopharma USA, Inc.	61476010410	Alyglo 10% Liquid 10g/100 ml	3/22/2024
GC Biopharma USA, Inc.	61476010420	Alyglo 10% Liquid 20g/200 ml	3/22/2024

Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally


The estimated volume of patients who may be prescribed the drug	
	500,000
	500,000
	500,000

Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval

N

N

N

Date and price of acquisition if the drug was not developed by the manufacturer
N/A
N/A
N/A